NAVIDEA BIOPHARMACEUTICALS I (NAVB) Stock Overview
USA - NYSEARCA:NAVB - US63937X2027 - Common Stock
NAVB Key Statistics, Chart & Performance
The current stock price of NAVB is 0.0779 USD. In the past month the price decreased by -15.33%. In the past year, price decreased by -68.58%.
NAVB Latest News, Press Relases and Analysis
NAVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.83B | ||
| AMGN | AMGEN INC | 13.35 | 156.75B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 149.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 107.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 62.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.73B | ||
| ARGX | ARGENX SE - ADR | 90.1 | 51.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.09 | 34.65B | ||
| INSM | INSMED INC | N/A | 34.67B | ||
| NTRA | NATERA INC | N/A | 26.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.49B | ||
| BIIB | BIOGEN INC | 9.4 | 22.05B |
Related stock screener links
About NAVB
Company Profile
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. The company is headquartered in Dublin Ohio, Ohio and currently employs 11 full-time employees. The firm is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The company has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
Company Info
NAVIDEA BIOPHARMACEUTICALS I
Suite 300, 425 Metro Place North
Dublin Ohio OHIO 43017 US
CEO: Jed A. Latkin
Employees: 11
Phone: 16147937500.0
NAVIDEA BIOPHARMACEUTICALS I / NAVB FAQ
What does NAVB do?
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. The company is headquartered in Dublin Ohio, Ohio and currently employs 11 full-time employees. The firm is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The company has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
Can you provide the latest stock price for NAVIDEA BIOPHARMACEUTICALS I?
The current stock price of NAVB is 0.0779 USD. The price decreased by -2.99% in the last trading session.
What is the dividend status of NAVIDEA BIOPHARMACEUTICALS I?
NAVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of NAVB stock?
NAVB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the next earnings date for NAVB stock?
NAVIDEA BIOPHARMACEUTICALS I (NAVB) will report earnings on 2023-11-13, after the market close.
Can you provide the ownership details for NAVB stock?
You can find the ownership structure of NAVIDEA BIOPHARMACEUTICALS I (NAVB) on the Ownership tab.
NAVB Technical Analysis
NAVB Financial Highlights
Over the last trailing twelve months NAVB reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -39.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -209.43% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NAVB Forecast & Estimates
7 analysts have analysed NAVB and the average price target is 5.1 USD. This implies a price increase of 6446.85% is expected in the next year compared to the current price of 0.0779.